ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Sarcoma-pathology-for-clinicians

Date: 27 Sep 2014
Presenter: Angelo Dei Tos
Resources: Webcast
Topics: Pathology/Molecular Biology, Sarcoma

http://oncologypro.esmo.org/Meeting-Resourc...and-cyclin-D-CDK4-6-pathway-activated-tumors

AimSMARCB1 mutations are observed in the majority of malignant rhabdoid tumors (MRTs) rendering them dependent on cyclin D1 (CCND1) for genesis and survival. Genetic aberrations in CCND1 and CDK4 are frequent in neuroblastoma cell lines.

Date: 27 Sep 2014
Presenter: Birgit Geoerger
Resources: Abstract
Topics: Drug Development, Central Nervous System Malignancies, Sarcoma, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...ab-in-patients-with-giant-cell-tumor-of-bone

AimSurgical resection, the standard treatment for giant cell tumor of bone (GCTB), may be associated with severe morbidity and may not be curative for all lesions.

Date: 27 Sep 2014
Presenter: Stefano Ferrari
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Bone Sarcomas, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...tment-efficacy-in-Ewing-Sarcoma-A-GWAS-study

AimIn the collaborative Euro-EWING99 study (EE99), Ewing sarcoma patients (EW pts) received vincristine ifosfamide doxorubicin etoposide induction (VIDE); maintenance treatment was stratified by initial staging and histological response.

Date: 27 Sep 2014
Presenter: BRICE Fresneau
Resources: Abstract
Topics: Pathology/Molecular Biology, Sarcoma, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...-on-clinical-outcomes-in-subtypes-of-sarcoma

AimSarcomas are rare heterogenous mesenchymal tumors that have limited treatment options. Novel targeted therapies are needed for shifting the paradign of care in sarcomas.

Date: 27 Sep 2014
Presenter: Shailaja Raj
Resources: Abstract
Topics: Pathology/Molecular Biology, Sarcoma

http://oncologypro.esmo.org/Meeting-Resourc...iscussant-abstracts-1419PD-1420PD-and-1421PD

Date: 27 Sep 2014
Presenter: Robin Jones
Resources: Presentation, Webcast
Topic: Sarcoma

http://oncologypro.esmo.org/Meeting-Resourc...study-study-C-and-a-single-arm-study-study-S

AimT binds to the minor groove of DNA and blocks DNA repair machinery. In addition, T inhibits interactions of transcription factors with DNA. It has been reported that T is an active drug in TRS pts...

Date: 27 Sep 2014
Presenter: Tsukasa Yonemoto
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Sarcoma

http://oncologypro.esmo.org/Meeting-Resourc...lar-profiling-of-angiosarcomas-of-the-breast

AimAngiosarcoma of the breast is a rare, aggressive soft tissue neoplasm occurring as either a primary or secondary malignancy due to previous radiotherapy for breast carcinoma.

Date: 27 Sep 2014
Presenter: Edibaldo Silva
Resources: Abstract
Topics: Soft Tissue Sarcomas, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...discussant-abstracts-1422PD-1423PD-and-LBA46

Date: 27 Sep 2014
Presenter: Nicolas Penel
Resources: Presentation, Webcast
Topic: Sarcoma

http://oncologypro.esmo.org/Meeting-Resourc...bition-in-dedifferentiated-liposarcoma-DDLPS

AimWe evaluated the efficacy of the PI3K inhibitor GDC-0941 (GDC) in combination with the angiogenesis inhibitor pazopanib (PAZ) in DDLPS xenografts with proven PI3K/AKT pathway activation.

Date: 28 Sep 2014
Presenter: Patrick Schöffski
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Sarcoma, Translational Research